#None #BTL #EMFACE #Facial Treatment

BTL's EMFACE Surpasses 1 Million Treatments

In a stunning achievement, BTL’s EMFACE has claimed its place in history as the fastest-growing non-invasive facial lifting procedure by surpassing a remarkable milestone of 1 million treatments globally within just two years. Launched in 2022, EMFACE has quickly become the preferred choice for individuals seeking rejuvenation without the need for invasive procedures. The treatment is unique as it addresses not only the skin's surface but also the underlying facial muscles, aiming for a more natural and youthful appearance.

Developed by BTL, a renowned company in the medical technology sector, EMFACE is the first device-independent procedure that effectively targets facial muscles while enhancing skin quality. According to Dr. Yael Halaas, a prominent facial plastic surgeon from New York City, the innovation in EMFACE lies in its ability to stimulate the elevator muscles beneath the skin, enabling a lifting effect that was previously unattainable without injectables or traditional energy-based devices. This non-invasive approach eliminates the need for needles, minimalizes downtime, and reduces discomfort, a combination that has drawn widespread acclaim from both the medical community and patients.

Innovation at the Forefront of EMFACE

Recent expansions of EMFACE's capabilities include the introduction of specialized applicators designed specifically for submental and under-eye areas, further enhancing the versatility of the treatment. These advancements received enthusiastic responses during their debut at the IMCAS World Conference held in Paris in January 2025. Dr. Kyungkook Hong, a certified dermatologist from Seoul, emphasized that EMFACE stands out as a comprehensive facial multitasking platform that tailors treatment to individual patient needs—a significant breakthrough for anyone seeking aesthetic enhancements.

As EMFACE continues to gain traction, its integration into the treatment plans of various practitioners is rapidly increasing. Its capacity to complement existing injectable treatments is particularly noteworthy, rendering it an essential aspect of comprehensive facial rejuvenation strategies. Tomas Schwarz, CEO of BTL, remarked that achieving 1 million treatments in a mere two years underscores the cutting-edge technology of EMFACE and the substantial value it brings to medical practitioners. BTL maintains its commitment to enhancing this platform and advancing the future of non-invasive facial treatments.

For those interested in the revolutionary EMFACE technology, further details can be found at www.emface.com.

About BTL

Founded in 1993, BTL has become one of the world’s leading manufacturers in the medical equipment industry. With a robust team of over 500 engineers and more than 3,000 employees spread across 80 countries, BTL specializes in creating advanced, non-invasive solutions for various medical aesthetic treatments, ranging from body shaping to skin tightening. Among its prestigious product range are recognized brands like EMSCULPT NEO®, EMFACE®, and EMSELLA®, along with proprietary technologies such as HIFEM® and HIFES™. For more information about BTL and its offerings, please visit www.btlaesthetics.com.